Magnetisation transfer ratio analysis of normal appearing white matter in patients with familial and sporadic multiple sclerosis

M Siger-Zajdel, K Selmaj

Abstract

Objectives—To assess differences in magnetisation transfer ratio (MTR) analysis of normal appearing white matter (NAWM) in patients with familial multiple sclerosis (MS) and those with sporadic MS.

Methods—10 patients with familial MS, 10 patients with sporadic MS, and 10 healthy subjects were included in the study. Groups were matched according to the sex, age, disease duration, type of disease, EDSS, and MRI T1 and T2 lesion load. Magnetisation transfer imaging (MTI) with and without saturation pulse were performed. On the MTR map 16 different regions of interest of normal appearing white matter were analyzed.

Results—The mean MTR value of normal appearing white matter was significantly lower both in familial patients and those with sporadic MS compared with healthy subjects (33.8% vs 46.4%; 38.6% vs 46.4% respectively, p< 0.05). Additionally, patients with familial MS showed significantly lower mean MTR value than patients with sporadic MS (33.8% vs 38.6%, p<0.05). There was also significant regional variation of MTR values between these two groups of patients.

Conclusions—Lower and more widespread MTR abnormalities in patients with familial MS might indicate differences in the extent and nature of white matter pathology between familial and sporadic MS.

Key words: familial multiple sclerosis, magnetic resonance imaging, magnetisation transfer ratio

The incidence of familial multiple sclerosis (MS) has been estimated as between 3.6%-20% in the general MS population.1-4 Epidemiological data have shown that the risk of MS development in first degree relatives of patients is five to 40 times higher than in the general population.6-8 Additionally, Sadovnick et al9 in a population based study estimated that MS would develop in 2%-3% of non-twin siblings and 3%-5% of children of patients with MS. Moreover, the incidence of MS has been shown to be 2%-5% and 25%-30% in dizygotic and monozygotic twins, respectively.11-12 This suggests that multiple genetic factors influence the occurrence of MS.13-14 On the other hand environmental factors have also been considered in MS predispositions.15-16 Although demographic and clinical differences between patients with familial and those with sporadic MS are not significant there is still ongoing discussion on the distinction between these two forms of the disease.17-18

Magnetic resonance imaging is the most sensitive paraclinical tool to demonstrate focal brain and spinal cord abnormalities in MS.19 However, several necropsy studies disclosed more widespread white matter pathology, including microscopical demyelination and cellular infiltration, which were not detectable on conventional MRI. These findings suggested that pathology in MS in not restricted to the focal lesions but extended to the adjacent white matter.20-22 To detect this subtle, microscopical white matter pathology in MS, magnetisation transfer imaging (MTI) can be applied. This is based on chemical exchange and cross relaxation between two pools of protons (bound and free protons).23-24 This transfer can be quantified as a magnetisation transfer ratio (MTR), which indirectly indicates destruction of the macromolecular matrix.25

There are a few reports concerning conventional MRI in patients with familial MS26-28 and there are no data on MTR comparison between patients with familial MS and patients with sporadic MS. In this study we have compared mean MTR and regional MTR values in normal appearing white matter in patients with these two forms of the disease.

Patients and methods

Patients with familial MS were defined as probands with one or more relatives having MS within one family (multiplex families). They were selected from clinical records of the Department of Neurology All available records were analysed and MS probands and their affected relatives were included in the study. For final analysis only patients with complete clinical history and with clinically definite MS according to the Poser criteria27 were included. Ten patients with MS from 10 multiplex families with MS (five women and five men, six with a relapsing-remitting and four with a secondary progressive course of disease) and 10 patients with sporadic MS (five women and five men, six with a relapsing-remitting, four with a secondary progressive course) were included in the study. All patients were examined neurologically and their clinical status was measured using the expanded disability status scale (EDSS). To avoid any effect of demographic and clinical characteristics on MTR results, both MS groups, familial and sporadic, were adequately matched. None of the patients had
had relapses or steroid treatment during the 5 months preceding study entry. Additionally, they had neither immunosuppressive nor immunomodulative treatment during the 6 months before the study. Both groups were also standardized according to T1 and T2 image burden (table 1). Additionally, 10 healthy subjects age and sex matched with the patients entered the study as a control group. All subjects gave written, informed consent before entering the study, which had been approved by the local ethics committee.

Table 1 Clinical and conventional MRI results in familial and sporadic MS patients

<table>
<thead>
<tr>
<th></th>
<th>Familial MS patients</th>
<th>Sporadic MS patients</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>1/1</td>
<td>1/1</td>
<td>1</td>
</tr>
<tr>
<td>Mean age (SD) (y)</td>
<td>35.6 (4.30)</td>
<td>33.7 (2.91)</td>
<td>33.5 (3.37)</td>
</tr>
<tr>
<td>Mean duration of disease (SD) (y)</td>
<td>6 (1.2)</td>
<td>5 (2.1)</td>
<td></td>
</tr>
<tr>
<td>Mean EDSS (SD)</td>
<td>4.0 (1.33)</td>
<td>4.0 (0.91)</td>
<td></td>
</tr>
<tr>
<td>Mean T1 lesion load (mm³)</td>
<td>230.0 (111.21)</td>
<td>310.1 (211.34)</td>
<td></td>
</tr>
<tr>
<td>Mean T2 lesion load (mm³)</td>
<td>2662.40 (93.78)</td>
<td>2569.30 (47.61)</td>
<td></td>
</tr>
</tbody>
</table>

**IMAGE ACQUISITION**

All examinations were performed on the same 1.5 T MR system (Vision, Siemens, Erlangen, Germany). In all patients the following sequences were acquired during a single session: (1) dual echo; repetition time (TR) 4500 ms; first echo time (TE) 22 ms; second echo TE 90 ms; section thickness 3 mm, intersection gap 0.1 mm, 23 slices, matrix 190×256; number of acquisitions and two dimensional gradient echo (GE; TR 800 ms; TE 10 ms; flip angle 30 degrees; slice thickness 3 mm, intersection gap 0.1 mm, 23 slices, matrix 192×256) with and without saturation pulse (off resonance RF pulse centred 1.5 kHz below the water frequency, gaussian envelope duration 14.3 ms, a band width 130 Hz, and an amplitude of 3.13×10⁴ T) were obtained. The slices in all sequences were positioned to run parallel to a line that joins the most inferoposterior parts of the corpus callosum according to published guidelines.

**IMAGE ANALYSIS**

Firstly, macroscopic MS lesions were identified by a single observer (unaware of the identity of the patients) on T2 and T1 weighted images. T1 weighted lesions were defined as an area of signal intensity without the saturation pulse.\(^2^4\) A magnetisation transfer ratio (MTR) map was calculated from the two GE images, with and without the saturation pulse, on a pixel by pixel basis from the formula:

\[ \text{MTR} = \frac{(\text{Mo} - \text{Ms})}{\text{Mo}} \times 100 \]

where Ms represents signal intensity with the saturation pulse and Mo represents signal intensity without the saturation pulse.\(^2^4\)

![Image 1](http://jnnp.bmj.com/)

**STATISTICAL ANALYSIS**

Comparisons between different types of patients and the control group for MTR data were assessed using one way analysis of variance (ANOVA). For post hoc analysis, multiple comparison tests with Bonferroni correction were used. For detailed analysis of MTR ROI differences between each pair of subjects an additional multiple comparison test was used (Duncan’s test). To compare clinical
data and conventional MRI results the Mann-Whitney U test was performed. Statistical significance was defined as p<0.05.

Results

No white matter signal abnormalities were found in the control group. In MRI of all patients, white matter lesions fulfilled the MS criteria proposed by Barkhof et al.30 Both MS groups were matched for T1 and T2 lesion load (p>0.05 for both indices; table 1).

The mean MTR values of all analyzed groups are given in table 2. Compared with the control group, the mean MTR obtained from patients with familial MS as well as from patients with sporadic MS was significantly lower (p<0.05). Interestingly, we also found significantly lower mean MTR values in patients with familial MS compared with sporadic patients (p<0.05).

Analysis of ROIs showed that in both familial and sporadic groups of patients mean MTR values in most analyzed regions were significantly lower than in the control group (p<0.05; tables 3 and 4). Additionally, mean MTR values in most of ROIs of the patients with familial MS were significantly lower than in the sporadic group (p<0.05; tables 3 and 4). Particularly, significantly lower MTR were detected in patients (both groups) compared with the control in the centrum semiovale, corpus callosum (genu), frontal white matter, cerebellum, and cerebellar peduncles. Also the highest difference in MTR between familial and patients with sporadic MS was detected in the corpus callosum, cerebral peduncles, and cerebellar peduncles. There were no differences in mean MTR values between right and left hemispheric ROIs in all groups included in the study.

Discussion

Although conventional MRI showing focal lesions has been established as the most important paraclinical tool for diagnosis and monitoring efficacy of treatment in MS, necropsy studies indicated that the MS pathological process is not restricted to the focal lesions but is extended to the adjacent white matter.20–22 Most of these subtle microscopic lesions remain beyond the resolution of conventional MRI.37 To gain more data for total disease burden, also that beyond the resolution of conventional MRI, MTR has been applied; this provides information on the integrity of the macromolecular matrix and correlates with extension of pathological process in MS.35 In the healthy population MTR values of the white matter was assessed to be between 32.0% and 50.8%.36–34 It has been shown that the MTR values for normal appearing white matter in patients with sporadic MS were decreased compared with the control group.34–36 Additionally, abnormal MTR values of normal appearing white matter were detected in patients with sporadic MS with negative conventional brain MRI.37 It has also been shown that there were no differences in mean MTR value between asymptomatic relatives of patients with sporadic MS and healthy persons.38 Astonishingly, there are no data on direct MTR comparison of normal appearing white matter between patients with familial and sporadic MS. We have conducted such a comparative MTR analysis, which aimed to contribute to the discussion on heterogeneity of MS and possible differentiation between familial and sporadic MS.

Although demographic and clinical data do not provide support for viewing familial MS as distinct from the sporadic form of disease, it is tempting to speculate that some peculiarities and differences still exist. In families heavily loaded with MS there was earlier onset of the disease and the male/female ratio was greater.39 Another argument that MS heterogeneity may have a genetic basis is relevant to patients with familial MS.35–34 A higher proportion of patients with familial MS experienced a progressive clinical course of disease. Consistently with these findings, we have found lower MTR values for normal

Table 2  Comparison of mean MTR values (SD) between all investigated groups

<table>
<thead>
<tr>
<th>Location</th>
<th>Familial MS patients (%)</th>
<th>Sporadic MS patients (%)</th>
<th>Control group (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centrum semiovale*</td>
<td>34.1 (0.20)</td>
<td>32.1 (0.12)</td>
<td>47.9 (0.11)</td>
</tr>
<tr>
<td>Corpus callosum (genu)</td>
<td>29.7 (0.62)</td>
<td>38.4 (0.25)</td>
<td>48.9 (0.20)</td>
</tr>
<tr>
<td>Corpus callosum (splenium)</td>
<td>32.5 (0.40)</td>
<td>42.4 (0.17)</td>
<td>42.6 (0.17)</td>
</tr>
<tr>
<td>Frontal white matter*</td>
<td>37.1 (0.20)</td>
<td>36.1 (0.18)</td>
<td>49.2 (0.17)</td>
</tr>
<tr>
<td>Occipital white matter*</td>
<td>35.7 (0.18)</td>
<td>38.6 (0.14)</td>
<td>43.6 (0.14)</td>
</tr>
<tr>
<td>Internal capsule*</td>
<td>34.4 (0.14)</td>
<td>36.6 (0.09)</td>
<td>43.8 (0.11)</td>
</tr>
<tr>
<td>Cerebellar peduncle*</td>
<td>32.7 (0.10)</td>
<td>44.9 (0.11)</td>
<td>44.7 (0.12)</td>
</tr>
<tr>
<td>Cerebellar peduncle*</td>
<td>33.5 (0.17)</td>
<td>41.1 (0.12)</td>
<td>50.0 (0.11)</td>
</tr>
<tr>
<td>Cerebellum*</td>
<td>33.4 (0.17)</td>
<td>37.4 (0.11)</td>
<td>47.9 (0.18)</td>
</tr>
</tbody>
</table>

*p Value obtained from one way analysis of variance (ANOVA) with Bonferroni correction.

Table 3  Mean MTR values (SD) in 16 regions of interest

<table>
<thead>
<tr>
<th>Location</th>
<th>Familial MS patients (%)</th>
<th>Sporadic MS patients (%)</th>
<th>Control group (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centrum semiovale*</td>
<td>34.1 (0.20)</td>
<td>32.1 (0.12)</td>
<td>47.9 (0.11)</td>
</tr>
<tr>
<td>Corpus callosum (genu)</td>
<td>29.7 (0.62)</td>
<td>38.4 (0.25)</td>
<td>48.9 (0.20)</td>
</tr>
<tr>
<td>Corpus callosum (splenium)</td>
<td>32.5 (0.40)</td>
<td>42.4 (0.17)</td>
<td>42.6 (0.17)</td>
</tr>
<tr>
<td>Frontal white matter*</td>
<td>37.1 (0.20)</td>
<td>36.1 (0.18)</td>
<td>49.2 (0.17)</td>
</tr>
<tr>
<td>Occipital white matter*</td>
<td>35.7 (0.18)</td>
<td>38.6 (0.14)</td>
<td>43.6 (0.14)</td>
</tr>
<tr>
<td>Internal capsule*</td>
<td>34.4 (0.14)</td>
<td>36.6 (0.09)</td>
<td>43.8 (0.11)</td>
</tr>
<tr>
<td>Cerebellar peduncle*</td>
<td>32.7 (0.10)</td>
<td>44.9 (0.11)</td>
<td>44.7 (0.12)</td>
</tr>
<tr>
<td>Cerebellar peduncle*</td>
<td>33.5 (0.17)</td>
<td>41.1 (0.12)</td>
<td>50.0 (0.11)</td>
</tr>
<tr>
<td>Cerebellum*</td>
<td>33.4 (0.17)</td>
<td>37.4 (0.11)</td>
<td>47.9 (0.18)</td>
</tr>
</tbody>
</table>

*p For the hemispheric regions, both right and left hemisphere values for MTR were included in the analysis.

Table 4  Significance (p values*) of ROI MTR differences between all investigated groups

<table>
<thead>
<tr>
<th>Location</th>
<th>Familial MS v control</th>
<th>Sporadic MS v control</th>
<th>Familial MS v sporadic MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centrum semiovale*</td>
<td>0.00014‡‡‡</td>
<td>0.00006</td>
<td>0.00014</td>
</tr>
<tr>
<td>Corpus callosum (genu)</td>
<td>0.00006</td>
<td>0.00014</td>
<td>0.00014</td>
</tr>
<tr>
<td>Corpus callosum (splenium)</td>
<td>0.00006</td>
<td>0.10867</td>
<td>0.00014</td>
</tr>
<tr>
<td>Frontal white matter†</td>
<td>0.00006</td>
<td>0.00014</td>
<td>0.00014</td>
</tr>
<tr>
<td>Occipital white matter†</td>
<td>0.00006</td>
<td>0.00014</td>
<td>0.00014</td>
</tr>
<tr>
<td>Internal capsule†</td>
<td>0.00006</td>
<td>0.00014</td>
<td>0.00014</td>
</tr>
<tr>
<td>Cerebellar peduncle†</td>
<td>0.00006</td>
<td>0.00014</td>
<td>0.00014</td>
</tr>
<tr>
<td>Cerebellum†</td>
<td>0.00006</td>
<td>0.00014</td>
<td>0.00014</td>
</tr>
</tbody>
</table>

MS=Multiple sclerosis.

*Multiple comparison test.
†For the hemispheric regions, both right and left hemisphere values for MTR were included in the analysis.
‡MTF lower in familial than in sporadic MS patients.
§MTF higher in familial than in sporadic MS patients.
‖MTF higher in sporadic MS patients than in controls.

www.jnnp.com
appearing white matter in patients with familial MS compared with patients with sporadic MS. We conclude that this difference is not caused by demographic or clinical features of the patient groups, as we have matched patients with familial MS and patients with sporadic MS for all variables which have been suggested to influence the MTR value. These variables included sex, age, time from the beginning of disease, EDSS, type of disease, and total T1 and T2 lesion volume.24–34 There are no data on association between genetic polymorphism and familial MS but recently it has been suggested that genetic factors, Apo E4 isoform,19 interleukin 1β and interleukin 1 receptor antagonist,45–47 Fc gamma RIIH, and Fc-gamma RIA44 are implicated in more progressive, severe forms of MS. Therefore, it might be tempting to speculate that in familial MS more widespread tissue destruction as detected by MTR might result from a genetic predisposition.

Apart from differences in mean MTR values between patients with familial MS and those with sporadic MS we have also found significant variations of MTR values in specific brain location (ROI analysis). In familial MS we found lower MTR values in most ROIs compared to with the sporadic group but the most significant differences have occurred in the corpus callosum and in cerebral and cerebellar peduncles. This finding is of interest as focal MS lesions on MRI have also shown a tendency to occur in these locations with higher frequency.40 This would indicate that in familial MS the prevalence formation time is prolonged. Therefore, one possible explanation of our findings is that in familial patients reduction of MTR in normal appearing white matter might have preceded new lesion formation.40 Another possible explanation for such MTR ROI variation is that the nature of the changes in normal appearing white matter may be slightly different in familial and sporadic MS. Therefore, our results might indicate that in patients with familial MS the pathological processes spread more actively to the regions of highly myelinated white matter. This is in agreement with the results of a previous study indicating widespread white matter hypome-tabolism in patients with MS.40 Our results on the widespread decreases in MTR in white matter in patients with MS might explain functional deterioration by impairing axonal brain function and cortical and subcortical connectivity. The extent of decreases in MTR in patients with familial MS will have to be fully defined by MTR histogram analysis but our data indicate that widespread changes might be the MRI hallmark for familial MS.

The nature of discrete changes beyond the resolution of conventional MRI responsible for our MTR findings can only be speculative. However, the recent data on the correlation of decreased normal appearing white matter MTR values with brain atrophy suggests that tissue loss might be primarily responsible for the reduced value of MTR in MS brains.46 Axonal loss, either primary or secondary to focal abnormalities, resulting in wallerian degeneration should be considered in this regard. Postmortem study, both in humans and animals, showed a strong correlation between low MTR values and axonal loss.50 Additionally, in a recently published study myelin and axonal loss seemed to be the most likely contributors to the increased diffusivity in normal appearing white matter.50

In conclusion, our data suggest that there are differences in MTR analysis of normal appearing white matter in patients with familial MS and patients with sporadic MS. Patients with familial MS showed lower mean MTR values and more widespread MTR abnormalities. These findings might indicate slight differences in the extent and nature of white matter pathology in familial and sporadic MS.

This study was supported by a grant from KBN 4P05B112114 and the City Council of Lodz. We thank Dr Massimo Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San Raffaele, Milan, for helpful advice and critical discussion of our results.

Magnetisation transfer ratio analysis of normal appearing white matter in patients with familial and sporadic multiple sclerosis

M Siger-Zajdel and K Selmaj

*J Neurol Neurosurg Psychiatry* 2001 71: 752-756
doi: 10.1136/jnnp.71.6.752

Updated information and services can be found at:
http://jnnp.bmj.com/content/71/6/752

**These include:**

**References**

This article cites 45 articles, 20 of which you can access for free at:
http://jnnp.bmj.com/content/71/6/752#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1943)
- Multiple sclerosis (934)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/